AOD-9604 vs HGH Fragment 176-191.

AOD-9604 ("Advanced Obesity Drug 9604") is a synthetic 16-amino-acid peptide corresponding to the C-terminal lipolytic region of human growth hormone (hGH), residues 177–191, with an added tyrosine at the N-terminus. It was engineered in the 1990s by researchers at Monash University and developed by the Australian biotech Metabolic Pharmaceuticals as an orally-investigated anti-obesity agent. The design goal was to isolate hGH's fat-mobilizing activity while leaving out the growth-promoting, IGF-1-stimulating actions of the full hormone.

HGH Fragment 176-191 is a synthetic peptide corresponding to the final 16 amino acids (residues 176 to 191) of the C-terminal region of human growth hormone. It derives from the observation that this domain appears to carry GH's fat-metabolizing (lipolytic) activity while lacking the growth-promoting and insulin-antagonizing actions of the whole hormone. It is closely related to, but distinct from, AOD-9604, a modified analog in which a tyrosine residue is added to the N-terminus (developed under the name Anti-Obesity Drug 9604). The plain 176-191 fragment itself is a research-only compound with almost no dedicated clinical data.

In rodent models, AOD-9604 reproduces the lipolytic (fat-breakdown) and fat-oxidation–promoting effects of full-length growth hormone without binding the GH receptor and without raising IGF-1. Mechanistic work in obese and beta-3-adrenergic-receptor knockout mice indicated its effect on fat metabolism is associated with modulation of beta-3 adrenergic receptor activity and increased lipolysis and fat oxidation rather than classic GH-receptor signaling. Because it does not engage the GH receptor, it was hypothesized to avoid the insulin-resistance and tissue-growth liabilities of GH itself. Importantly, the cleanly receptor-independent, IGF-1-sparing profile is best characterized in animal and in-vitro work, not firmly established in humans.

The proposed mechanism is stimulation of lipolysis, the breakdown of stored triglycerides, along with reduced fat synthesis in adipose tissue, reproducing the fat-reducing effect of GH's C-terminus without activating the GH receptor to raise IGF-1 or impair glucose handling. Work on the analog AOD-9604 implicated the beta-3-adrenergic pathway in this effect. The mechanism is characterized mainly in mouse and in vitro models, and how faithfully the unmodified 176-191 fragment reproduces it in humans is not established.

Preclinical evidence is the strongest part of the AOD-9604 record: chronic dosing reduced body-weight gain and increased fat oxidation in obese mice (Heffernan et al., Int J Obes, 2001; PMID 11673763). It progressed into human obesity trials in the early-mid 2000s; a 12-week randomized study reported only a modest separation from placebo (on the order of ~1–2 kg), and development was halted around 2007 after a larger ~24-week trial failed to show meaningful weight-loss efficacy, particularly once diet and exercise were standardized. No peer-reviewed pivotal trial demonstrates clinically useful weight loss, and there is no robust human evidence for the commonly marketed claims around cartilage, joint, or tendon repair: those rest on limited preclinical/early work. In short, the human data are negative-to-thin for obesity and largely absent for other indications.

Almost all supportive data come from the modified analog AOD-9604 rather than from 176-191 itself. Heffernan et al., in Endocrinology (2001, PMID 11713213), showed that AOD9604 reduced body weight and increased lipolysis in obese mice and that the effect disappeared in beta-3-adrenergic-receptor knockout mice, implicating that pathway. That was a rodent study using genetically obese and knockout strains, with short treatment periods and body-weight and tissue endpoints rather than clinical outcomes. Its central finding, dependence on a receptor whose contribution to human fat metabolism is far smaller than in rodents, is itself a reason to doubt direct translation. AOD-9604 was later carried into human obesity trials but did not produce clinically meaningful weight loss beyond placebo and was not approved as a drug. The program, run by an Australian sponsor, was discontinued after the larger placebo-controlled trial failed to separate from placebo on weight, which is the endpoint that matters for an anti-obesity indication. The compound was subsequently repositioned toward non-pharmaceutical uses, and a separate strand of published work examined intra-articular AOD9604 in a rabbit osteoarthritis model rather than obesity, which says nothing about systemic fat loss. For the unmodified 176-191 fragment specifically there is essentially no controlled human evidence, and its reputation is extrapolated from AOD-9604 data. The tyrosine added to the N-terminus of AOD-9604 was a deliberate stability modification, so the two molecules are not interchangeable, and no published head-to-head comparison establishes that the plain fragment behaves like the analog in people. The contrast with full-length somatropin is instructive: recombinant GH has approved indications, product labeling, decades of registry data, and a well-mapped metabolic profile, while the fragment has none of that. There are no human pharmacokinetic data for 176-191, no bioavailability data, no dose-ranging work, no imaging-based body-composition endpoints, and no long-term study of any kind.

Across the obesity trials, AOD-9604 was generally reported as well tolerated with a clean short-term safety signal, which is part of why it was later nominated for compounding review; however, these data come from time-limited studies and do not establish long-term safety. There is no established safety profile for chronic use, for injectable research-grade ("gray market") product, or for the unindicated cosmetic, joint, and anti-aging uses now marketed online. Purity, identity, and contamination of non-pharmaceutical material are real concerns, underscored by published forensic identification of illicit AOD9604 preparations (Drug Testing and Analysis, 2014; PMID 24976118). No dosing or administration guidance is provided here.

In its trials the analog AOD-9604 was generally well tolerated over short periods, with headache and mild edema among the reported effects, but the plain 176-191 fragment has no comparable human safety record of its own. Long-term safety is unknown. The theoretical selling point of the fragment, that it separates GH's lipolytic action from the growth-promoting and insulin-antagonizing actions of the whole hormone, has never been confirmed in a controlled human study, so the assumption that it avoids GH's metabolic liabilities remains an assumption rather than a finding. Full-length growth hormone reliably raises IGF-1 and can worsen glucose tolerance and cause fluid retention, carpal tunnel symptoms, and arthralgia. Whether a C-terminal fragment is genuinely free of those effects at meaningful exposure is untested, and no study has measured IGF-1 or glucose handling during sustained exposure to the fragment. Because the peptide is administered by injection, the usual injection risks apply: local reactions, infection from non-sterile technique or non-sterile product, and immune response to a foreign fragment. Nothing published characterizes immunogenicity for this sequence. Injectable material sold online as Fragment 176-191 is unregulated research-grade product of uncertain identity and purity, frequently supplied without a certificate of analysis or with one that cannot be traced to the vial in hand, and independent testing of this market has found mislabeled and contaminated product. A proper trial would require fasting glucose and insulin, IGF-1, and lipid monitoring, together with sterility and endotoxin testing of the material, none of which happens outside a regulated setting. The safety of the fragment itself remains largely uncharacterized.

AOD-9604 is not approved by the FDA (or any major regulator) for any therapeutic use; its obesity development program was discontinued, and it remains investigational/research-use-only. The FDA has evaluated it among nominated bulk drug substances for pharmacy compounding under section 503A and has flagged peptide candidates of this type as raising significant safety questions; it is also prohibited in sport and tested for by anti-doping authorities under the WADA framework.

HGH Fragment 176-191 is not an approved drug and is sold as research-use-only. The related AOD-9604 was investigated for obesity, failed to reach approval as a pharmaceutical, and was subsequently pursued as a food and cosmetic ingredient in some markets; neither has FDA approval as a weight-loss medicine. GH fragments of this type are prohibited in sport by WADA.